KemPharm, Inc. (KMPH)’s H&S Points to Higher Stock Risks

June 14, 2018 - By Clifton Ray

KemPharm, Inc. (NASDAQ:KMPH) Logo

The stock of KemPharm, Inc. (KMPH) formed H&S with $5.75 target or 8.00 % below today’s $6.25 share price. The 7 months Head & Shoulders indicates high risk for the $98.49M company. It was reported on Jun, 14 by Faxor.com. If the $5.75 price target is reached, the company will be worth $7.88 million less.
Head-and-shoulders are one of the best chart patterns to trade. They work in bear and bull markets and according to many researchers have very low failure rate. Even thought they have high pullback rate, such patters usually provide good risk-reward entry opportunities. The percentage of stocks meeting price targets is 55%.

The stock decreased 2.34% or $0.15 during the last trading session, reaching $6.25. About 99,883 shares traded. KemPharm, Inc. (NASDAQ:KMPH) has risen 51.19% since June 14, 2017 and is uptrending. It has outperformed by 38.62% the S&P500.

Analysts await KemPharm, Inc. (NASDAQ:KMPH) to report earnings on August, 9. They expect $-0.98 earnings per share, down 122.73 % or $0.54 from last year’s $-0.44 per share. After $-1.11 actual earnings per share reported by KemPharm, Inc. for the previous quarter, Wall Street now forecasts -11.71 % EPS growth.

KemPharm, Inc. (NASDAQ:KMPH) Ratings Coverage

Among 5 analysts covering KemPharm (NASDAQ:KMPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. KemPharm has $17 highest and $9.0 lowest target. $11.90’s average target is 90.40% above currents $6.25 stock price. KemPharm had 7 analyst reports since January 16, 2018 according to SRatingsIntel. The company was maintained on Monday, April 2 by Oppenheimer. The rating was maintained by Oppenheimer with “Buy” on Sunday, February 25. The rating was maintained by Canaccord Genuity with “Buy” on Monday, February 26. Roth Capital maintained KemPharm, Inc. (NASDAQ:KMPH) rating on Monday, April 2. Roth Capital has “Buy” rating and $9.5000 target. The firm has “Buy” rating by RBC Capital Markets given on Tuesday, January 16. The firm has “Buy” rating given on Friday, February 23 by Canaccord Genuity.

More recent KemPharm, Inc. (NASDAQ:KMPH) news were published by: Seekingalpha.com which released: “Reader Inquiry: With Key Catalysts In 2019, Is Minerva Neurosciences A Buy?” on May 31, 2018. Also Seekingalpha.com published the news titled: “FDA OKs first non-opioid treatment for opioid withdrawal” on May 16, 2018. Benzinga.com‘s news article titled: “Janney Buys Into KemPharm Ahead Of ‘Transformative’ Summer Catalyst” with publication date: May 23, 2018 was also an interesting one.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. The company has market cap of $98.49 million. The Company’s lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. It currently has negative earnings. The firm is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders.

KemPharm, Inc. (NASDAQ:KMPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: